BRE Antibody

Code CSB-PA080030
Size US$100
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
BABAM2
Alternative Names
6030405P19Rik antibody; AI429776 antibody; B830038C02Rik antibody; Brain and reproductive organ expressed (TNFRSF1A modulator) antibody; brain and reproductive organ expressed protein antibody; Brain and reproductive organ-expressed protein antibody; BRCA1 A complex subunit BRE antibody; BRCA1-A complex subunit BRE antibody; BRCA1/BRCA2 containing complex subunit 4 antibody; BRCA1/BRCA2 containing complex subunit 45 antibody; BRCA1/BRCA2-containing complex subunit 45 antibody; BRCC4 antibody; BRCC45 antibody; bre antibody; BRE_HUMAN antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Synthesized peptide derived from the C-terminal region of Human BRE.
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form
Liquid
Tested Applications
WB, ELISA
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:2000
ELISA 1:10000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). The BRCA1-A complex also possesses deubiquitinase activity that specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX. In the BRCA1-A complex, it acts as an adapter that bridges the interaction between BABAM1/NBA1 and the rest of the complex, thereby being required for the complex integrity and modulating the E3 ubiquitin ligase activity of the BRCA1-BARD1 heterodimer. Component of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates. Within the BRISC complex, acts as an adapter that bridges the interaction between BABAM1/NBA1 and the rest of the complex, thereby being required for the complex integrity. The BRISC complex is required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1. The BRISC complex plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1; deubiquitination increases IFNAR1 activity by enhancing its stability and cell surface expression. Down-regulates the response to bacterial lipopolysaccharide (LPS) via its role in IFNAR1 deubiquitination. May play a role in homeostasis or cellular differentiation in cells of neural, epithelial and germline origins. May also act as a death receptor-associated anti-apoptotic protein, which inhibits the mitochondrial apoptotic pathway. May regulate TNF-alpha signaling through its interactions with TNFRSF1A; however these effects may be indirect.
Gene References into Functions
  1. Results show that BRE expression is regulated by HOTTIP LncRNA. Its over-expression promotes cell proliferation and cell cycle progression inhibiting apoptosis of glioma cells. PMID: 27733185
  2. High BRE and high EVI1 expression are mutually exclusive in MLL-AF9-positive acute myeloid leukemia patients. PMID: 22555662
  3. High BRE expression defines a novel subtype of adult acute myeloid leukemia characterized by a favorable prognosis. PMID: 21937695
  4. NBA1/MERIT40 and BRE interaction is required for the integrity of two distinct deubiquitinating enzyme BRCC36-containing complexes PMID: 21282113
  5. overexpression of the BRE gene is predominantly found in MLL-rearranged AML with t(9;11)(p22;q23). PMID: 20861917
  6. A novel stress-responsive gene called BRE which interacts with TNF-receptor-1 and blocks the apoptotic effect of TNF-alpha, was identified. PMID: 19757177
  7. These results show that BRE over-expression can indeed promote growth, though not initiation, of liver tumors. PMID: 20035718
  8. BRE mediates antiapoptosis by inhibiting the mitochondrial apoptotic machinery PMID: 15465831
  9. the enhanced tumor growth is more likely due to the antiapoptotic activity of BRE than any direct effect of the protein on cell proliferation PMID: 15582573
  10. Antiapoptotic in vivo; Bre levels are regulated post-transcriptionally in the liver, which is not observed in human hepatocellular carcinoma (HCC) and non-HCC cell lines. PMID: 17704801
  11. results implied that BRE plays a significant role in mediating antiapoptotic and proliferative responses in esophageal carcinoma cells PMID: 18756325

Show More

Hide All

Subcellular Location
Cytoplasm. Nucleus.
Protein Families
BABAM2 family
Tissue Specificity
Expressed in all cell lines examined. Highly expressed in placenta.
Database Links

HGNC: 1106

OMIM: 610497

KEGG: hsa:9577

STRING: 9606.ENSP00000343412

UniGene: Hs.258314

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*